Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-11-21
2006-11-21
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S050000, C514S051000, C514S108000, C514S107000, C514S118000
Reexamination Certificate
active
07138388
ABSTRACT:
This invention provides methods for treating inflammatory or autoimmune diseases by contacting the affected cell or tissue with a therapeutic compound as described herein. Such pathologies include, but are not limited to rheumatoid arthritis, systemic lupus erythmatosus, psoriatic arthritis, reactive arthritis, Crohn's disease, ulcerative colitis and scleroderma. Therapeutic compounds useful in the methods of this invention are selected from the group consisting of a 1,5-substituted pyrimidine derivative or analog and substituted furano-pyrimidone analog.
REFERENCES:
patent: 3852266 (1974-12-01), Kiyanagi et al.
patent: 4247544 (1981-01-01), Bergstrom et al.
patent: 4267171 (1981-05-01), Bergstrom et al.
patent: 4542210 (1985-09-01), Sakata et al.
patent: 4816570 (1989-03-01), Farquhar
patent: 4948882 (1990-08-01), Ruth
patent: 4975278 (1990-12-01), Senter et al.
patent: 5070082 (1991-12-01), Murdock et al.
patent: 5077282 (1991-12-01), Murdock et al.
patent: 5077283 (1991-12-01), Murdock et al.
patent: 5085983 (1992-02-01), Scanlon
patent: 5116827 (1992-05-01), Murdock et al.
patent: 5212161 (1993-05-01), Moriniere et al.
patent: 5212291 (1993-05-01), Murdock et al.
patent: 5233031 (1993-08-01), Borch et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5457187 (1995-10-01), Gmeiner et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5521161 (1996-05-01), Malley et al.
patent: 5616564 (1997-04-01), Rapaport
patent: 5627165 (1997-05-01), Glazier
patent: 5643893 (1997-07-01), Benson et al.
patent: 5645988 (1997-07-01), Vande Woude et al.
patent: 5663321 (1997-09-01), Gmeiner et al.
patent: 5705336 (1998-01-01), Reed et al.
patent: 5798340 (1998-08-01), Bischofberger et al.
patent: 5981507 (1999-11-01), Josephson et al.
patent: 6245750 (2001-06-01), Shepard
patent: 6589941 (2003-07-01), Fahrig et al.
patent: 6599499 (2003-07-01), Rosen et al.
patent: 982776 (1965-02-01), None
patent: WO 91/17424 (1991-11-01), None
patent: WO 93/06120 (1993-04-01), None
patent: WO 94/03467 (1994-02-01), None
patent: WO 94/22483 (1994-10-01), None
patent: WO 95/08556 (1995-03-01), None
patent: WO 96/03151 (1996-02-01), None
patent: WO 96/07413 (1996-03-01), None
patent: WO 96/10030 (1996-04-01), None
patent: WO 96/29336 (1996-09-01), None
patent: WO 96/40088 (1996-12-01), None
patent: WO 96/40708 (1996-12-01), None
patent: WO 97/28179 (1997-08-01), None
patent: WO 99/08110 (1999-02-01), None
patent: WO 99/20741 (1999-04-01), None
patent: WO 99/23104 (1999-05-01), None
patent: WO 99/37753 (1999-07-01), None
patent: WO 01/07088 (2001-02-01), None
patent: WO 01/07454 (2001-02-01), None
patent: WO 01/36686 (2001-05-01), None
patent: WO 2004/011625 (2004-02-01), None
Lackey et al. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochemical Pharmacology 2001, 61(2) pp. 179-189.
Abraham, T.W., et al. (1996) “Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2′-deoxyuridine and 1-β-arabinofuranosylcytosine: Evidence of phosphoramidase activity”J. Med. Chem.39:4569-4575.
Akdas, A., et al. (1996) “Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder”Eur. Urol.29:483-486.
Almasan, A., et al. (1995) “Genetic instability as a consequence of inappropriate entry into and progression through S-phase”Cancer&Metastasis Rev.14:59-73.
Almasan, A., et al. (Jun. 1995) “Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis”PNAS,USA 92:5436-5440.
Andersen, T.I., et al. (1995) “Detection of c-erbb-2 related protein in sera from breast cancer patients”Acta Oncol.34(4):499-504.
Anglada, J.M., et al. (Jul.-Aug. 1996) “N,N′-cyclization of carbodiimides with 2-(bromomethyl)acrylic acid. A direct entry to the system 5-methylene-6H-pyrimidine-2,4-dione, a new class of thymine analogues”J. Heterocyclic Chem.33:1259-1270.
Antelman, D., et al. (1995) “Inhibition of tumor cell proliferationin vitroandin vivoby exogenous p110RB, the retinoblastoma tumor suppressor protein”Oncogene10:697-704.
Asakura, J., et al. (1988) “Cerium(IV) catalyzed iodination at C5 of uracil nucleosides”Tetrahedron Lett.29(23):2855-2858.
Asakura, J., et al. (1990) “Cerium(IV)-mediated halogenation at C-5 of uracil derivatives”J. Org. Chem.55:4929-4933.
Aschele, C. et al. (Jun. 1999) “Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy”J. Clin. Oncol.17(6):1760-1770.
Ayisi, N. K., et al. (1933) “Comparison of the antiviral effects of 5-methoxymethyldeoxyuridine-5′-monophosphate with adenine arabinoside-5′-monophosphate”Antiviral Res.3:161-174.
Balzarini, J., et al. (1987) “Thmidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene”Mol. Pharmacol.32:410-416.
Balzarini, J., et al. (1993) “Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2”J. Biol. Chem.268(9):6332-6337.
Balzarini, J., et al. (1995) “Incorporation of 5-substituted pyrimidine nucleoside anologues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line”Meth. Find. Exptl. Clin. Pharmacol.7(1):19-28.
Balzarini, J., et al. (1996) “Anti-HIV and anti-HIV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109”Biochem. Biophys. Res. Commun.225:363-369.
Balzarini, J., et al. (1997) “Conversion of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-didehydro-2′,3′-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus”FEBS Lett.410:324-328.
Balzarini, J., et al. (Jul. 1996) “Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives”PNAS USA93:7295-7299.
Banerjee, D., et al. (1995) “Molecular mechanisms of resistance to antifolates, a review”Acta Biochemical Polonica42(4):457-464.
Banerjee, D., et al. (Oct. 1998) “Role of E2F-1 in chemosensitivity”Can. Res.58:4292-4296.
Barbato, S., et al. (1989) “Synthesis of bridged pyrimidine nucleosides and triazo [4, 3-c] pyrimidine nucleoside analogues”Nucleosides&Nucleotides8(4):515-528.
Barbour, K.W., et al. (1992) “A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2′-deoxyuridine in mammalian and bacterial cells”Mol. Pharmacol.42:242-248.
Barr, P.J., et al. (1981) “Inhibition of thymidylate synthetase by 5-alkynyl-2′-deoxyuridylates”J. Med. Chem.24(12):1385-1388.
Barr, P.J., et al. (1983) “Reaction of 5-ethynyl-2′-deoxyuridylate with thiols and thymidylate synthetase”Biochem.22:1696-1703.
Barr, P.J., et al. (1983) “Thymidylate synthetase-catalyzed conversions ofE-5-(2-Bromovinyl)-2′-deoxyuridylate”J. Biol. Chem.258(22):13627-13631.
Barrett, J.E., et al. (1998) “Trapping of the C5 methylene intermediate in thymidylate synthase”J. Am. Chem. Soc.120:449-450.
Belt, J.A., et al. (1993) “Nucleoside Transport in Normal and Neoplastic Cells”Advan. Enzyme Regul.33:235-252.
Benzaria, S., et al. (1996) “Synthesis,in vitroantiviral evaluation, and st
Celmed Oncology (USA), Inc.
Kim Jennifer
Wang Shengjun
LandOfFree
Methods to treat autoimmune and inflammatory conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to treat autoimmune and inflammatory conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to treat autoimmune and inflammatory conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3635806